CO5251425A1 - Metodo y composiciones para administrar taxanos oralmente a pacientes humanos - Google Patents
Metodo y composiciones para administrar taxanos oralmente a pacientes humanosInfo
- Publication number
- CO5251425A1 CO5251425A1 CO00082131A CO00082131A CO5251425A1 CO 5251425 A1 CO5251425 A1 CO 5251425A1 CO 00082131 A CO00082131 A CO 00082131A CO 00082131 A CO00082131 A CO 00082131A CO 5251425 A1 CO5251425 A1 CO 5251425A1
- Authority
- CO
- Colombia
- Prior art keywords
- taxane
- human patients
- administered
- oral
- orally
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Agentes antineoplásticos de taxano que hasta ahora han exhibido pobre o ninguna biodisponibilidad oral, se administran oralmente a pacientes humanos que sufren de condiciones de enfermedad que responden al taxano y se hace suficientemente biodisponible para alcanzar niveles sanguíneos terapéuticos. En una modalidad preferida, el taxano, preferiblemente paclitaxel, se co-administra al paciente con un agente mejorador de ciclosporina oral, preferiblemente ciclosporina A. Por un método preferido, se administra una dosis de mejorador oral aproximadamente 0.5-72 horas antes del taxano y una segunda dosis del mejorador y se administra inmediatamente antes, junto con o inmediatamente después del taxano. También se provee un método para tratar pacientes humanos que sufren de condiciones de enfermedad con respuesta al taxano, así como un método para proveer tal tratamiento a la vez que se previene o reduce la hipersensibilidad y las reacciones alérgicas sin necesidad de pre-medicación.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16231099P | 1999-10-27 | 1999-10-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO5251425A1 true CO5251425A1 (es) | 2003-02-28 |
Family
ID=22585092
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO00082131A CO5251425A1 (es) | 1999-10-27 | 2000-10-27 | Metodo y composiciones para administrar taxanos oralmente a pacientes humanos |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP1225956A1 (es) |
| JP (1) | JP2003512443A (es) |
| KR (1) | KR20030019296A (es) |
| CN (1) | CN1450923A (es) |
| AU (1) | AU1104201A (es) |
| BR (1) | BR0015149A (es) |
| CA (1) | CA2389583A1 (es) |
| CO (1) | CO5251425A1 (es) |
| CZ (1) | CZ20021484A3 (es) |
| HU (1) | HUP0203303A3 (es) |
| IL (1) | IL149360A0 (es) |
| MX (1) | MXPA02004164A (es) |
| NO (1) | NO20022008L (es) |
| PL (1) | PL354777A1 (es) |
| RU (1) | RU2002113659A (es) |
| SK (1) | SK5822002A3 (es) |
| WO (1) | WO2001030448A1 (es) |
| ZA (1) | ZA200203358B (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6750246B1 (en) | 2000-02-03 | 2004-06-15 | Bristol-Myers Squibb Company | C-4 carbonate taxanes |
| WO2002043765A2 (en) | 2000-11-28 | 2002-06-06 | Transform Pharmaceuticals, Inc. | Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof |
| AU2002357012A1 (en) * | 2001-11-27 | 2003-06-10 | Transform Pharmaceuticals, Inc. | Oral pharmaceutical formulations comprising paclitaxel, derivatives and methods of administration thereof |
| WO2004098570A1 (en) * | 2002-10-30 | 2004-11-18 | Spherics, Inc. | Nanoparticulate bioactive agents |
| US7345093B2 (en) | 2004-04-27 | 2008-03-18 | Formatech, Inc. | Methods of enhancing solubility of compounds |
| US7659310B2 (en) | 2004-04-27 | 2010-02-09 | Formatech, Inc. | Methods of enhancing solubility of agents |
| AR050043A1 (es) * | 2004-08-03 | 2006-09-20 | Novartis Ag | Metodos para mejorar la biodisponibilidad y composicion farmaceutica para trastornos cardiovasculares |
| CN101513395B (zh) * | 2008-02-20 | 2011-01-12 | 单宝华 | 紫杉醇类双层软胶囊口服制剂药物 |
| US9402812B2 (en) | 2009-09-23 | 2016-08-02 | Indu JAVERI | Methods for the preparation of liposomes |
| US10143652B2 (en) | 2009-09-23 | 2018-12-04 | Curirx Inc. | Methods for the preparation of liposomes |
| MX341082B (es) | 2010-05-03 | 2016-08-08 | Teikoku Pharma Usa Inc | Formulaciones de pro-emulsion de taxano no acuosas y metodos para hacer y usar las mismas. |
| JO3685B1 (ar) | 2012-10-01 | 2020-08-27 | Teikoku Pharma Usa Inc | صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها |
| JO3737B1 (ar) * | 2015-07-21 | 2021-01-31 | Athenex Therapeutics Ltd | تركيبات علاجية من باكليتاكسيل تعطى عن طريق الفم ومثبط P-gp لعلاج السرطان |
| EP4059497A1 (en) * | 2021-03-17 | 2022-09-21 | Dompé farmaceutici S.p.a. | C5ar1 inhibitors for treating hypersensitivity reactions to taxanes |
| EP4308114A1 (en) * | 2021-03-17 | 2024-01-24 | Dompe' Farmaceutici SpA | C5ar1 inhibitors for treating hypersensitivity reactions to taxanes |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6964946B1 (en) * | 1995-10-26 | 2005-11-15 | Baker Norton Pharmaceuticals, Inc. | Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same |
| US6245805B1 (en) * | 1995-10-26 | 2001-06-12 | Baker Norton Pharmaceuticals, Inc. | Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents |
| CA2221444A1 (en) * | 1996-01-31 | 1997-08-07 | Steven B. Hansel | A method of making pharmaceutically active taxanes orally bioavailable |
| US6025359A (en) * | 1996-06-17 | 2000-02-15 | Eli Lilly And Company | Drug resistance and multidrug resistance modulators |
| JP2002500667A (ja) * | 1997-05-27 | 2002-01-08 | ベーカー ノートン ファーマシューティカルズ インコーポレイテッド | 人間の患者に対して経口的にタキサン類を投薬するための方法及び組成物 |
| GB9718903D0 (en) * | 1997-09-05 | 1997-11-12 | Glaxo Group Ltd | Method,compositions and kits for increasing the oral bioavailability of pharmaceutical agents |
| AU756752B2 (en) * | 1998-04-01 | 2003-01-23 | Skyepharma Canada Inc. | Anticancer compositions |
| AU784416B2 (en) * | 1999-05-21 | 2006-03-30 | Abraxis Bioscience, Llc | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
-
2000
- 2000-10-27 HU HU0203303A patent/HUP0203303A3/hu unknown
- 2000-10-27 BR BR0015149-1A patent/BR0015149A/pt not_active IP Right Cessation
- 2000-10-27 CO CO00082131A patent/CO5251425A1/es not_active Application Discontinuation
- 2000-10-27 IL IL14936000A patent/IL149360A0/xx unknown
- 2000-10-27 JP JP2001532859A patent/JP2003512443A/ja active Pending
- 2000-10-27 CN CN00815924A patent/CN1450923A/zh active Pending
- 2000-10-27 MX MXPA02004164A patent/MXPA02004164A/es unknown
- 2000-10-27 RU RU2002113659/15A patent/RU2002113659A/ru not_active Application Discontinuation
- 2000-10-27 AU AU11042/01A patent/AU1104201A/en not_active Abandoned
- 2000-10-27 CZ CZ20021484A patent/CZ20021484A3/cs unknown
- 2000-10-27 WO PCT/US2000/029633 patent/WO2001030448A1/en not_active Application Discontinuation
- 2000-10-27 SK SK582-2002A patent/SK5822002A3/sk unknown
- 2000-10-27 PL PL00354777A patent/PL354777A1/xx not_active Application Discontinuation
- 2000-10-27 EP EP00972373A patent/EP1225956A1/en not_active Withdrawn
- 2000-10-27 KR KR1020027005396A patent/KR20030019296A/ko not_active Application Discontinuation
- 2000-10-27 CA CA002389583A patent/CA2389583A1/en not_active Abandoned
-
2002
- 2002-04-26 ZA ZA200203358A patent/ZA200203358B/en unknown
- 2002-04-26 NO NO20022008A patent/NO20022008L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| KR20030019296A (ko) | 2003-03-06 |
| CA2389583A1 (en) | 2001-05-03 |
| PL354777A1 (en) | 2004-02-23 |
| NO20022008L (no) | 2002-06-19 |
| ZA200203358B (en) | 2003-04-29 |
| CZ20021484A3 (cs) | 2003-12-17 |
| HUP0203303A3 (en) | 2005-01-28 |
| IL149360A0 (en) | 2002-11-10 |
| WO2001030448A1 (en) | 2001-05-03 |
| RU2002113659A (ru) | 2004-01-27 |
| JP2003512443A (ja) | 2003-04-02 |
| MXPA02004164A (es) | 2002-10-17 |
| NO20022008D0 (no) | 2002-04-26 |
| CN1450923A (zh) | 2003-10-22 |
| EP1225956A1 (en) | 2002-07-31 |
| BR0015149A (pt) | 2002-10-29 |
| HUP0203303A2 (hu) | 2003-02-28 |
| AU1104201A (en) | 2001-05-08 |
| SK5822002A3 (en) | 2003-01-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO5251425A1 (es) | Metodo y composiciones para administrar taxanos oralmente a pacientes humanos | |
| NO20014519D0 (no) | Apomorfin- og sildenafilpreparat | |
| MXPA05006940A (es) | Formulaciones terapeuticas para el tratamiento de enfermedades relacionadas con beta - amiloide. | |
| RU2007138867A (ru) | Режимы дозирования транс-кломифена | |
| RU2007119545A (ru) | Пегилированный липосомальный доксорубицин в комбинации с эктеинасцидином 743 (ecteinescidin 743) | |
| DE50203456D1 (de) | Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel | |
| AR048318A1 (es) | Formulaciones de matriz orales que comprenden licarbazepina | |
| BR9809694A (pt) | Processo e composição para administração de taxanos oralmente a pacientes humanos | |
| HK1077215A1 (en) | A pharmaceutical composition for treatment of acute myocardial infarction | |
| AR045263A1 (es) | Metodo, kit y composicion farmaceutica para tratar infecciones virales | |
| BRPI0414518A (pt) | composições farmacêuticas e métodos compreendendo combinações de derivados de 2-alquilideno-19-nor-vitamina d e hormÈnio paratireoidiano | |
| RU2005131578A (ru) | Аплидин для лечения множественной миеломы | |
| CA2516458A1 (en) | Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis | |
| PT1251850E (pt) | Utilizacao de uma preparacao de combinacao na terapia do cancro | |
| WO2001080895A3 (en) | Methods and compositions for the treatment of cardiac indications | |
| CA2368352A1 (en) | Method for treating neurodegeneration | |
| TW200501967A (en) | Nemorubicin for use in the preparation of a medicament for liver disease | |
| HK1040064A1 (en) | Beta-d-2',3'-didehydro-2',3'-dideoxy-5-fluorocytidine for use in the treatment of hiv infections | |
| NZ516026A (en) | Oral administration of taxanes to human patients using cyclosporins as bioavailability-enhancing agents | |
| Susman | Relapsed Mantle Cell Lymphoma: Thalidomide Adds to Rituximab's Potency | |
| RU2002113978A (ru) | Способ стимуляции моторной активности кишечника | |
| DK1265629T3 (da) | Anvendelse af væksthormon i lav dosis | |
| RU2006138043A (ru) | Способ лечения инсульта с применением введения дефибриногенизирующих средств для достижения специфического характера дефибриногенизации | |
| TH54155B (th) | วิธีการรักษาอาการประสาทเสื่อม | |
| AR043241A1 (es) | Terapia combinada que comprende un derivado de indolpirrol-carbazol y otro agente antitumoral |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Application refused |